Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03832647
Recruitment Status : Not yet recruiting
First Posted : February 6, 2019
Last Update Posted : February 6, 2019
Sponsor:
Information provided by (Responsible Party):
Vichy Laboratoires

Brief Summary:

Study to evaluate the anti-acne efficacy of a dermo-cosmetic associated with the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment and to demonstrate that the dermo-cosmetic product can improve the local tolerance of the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment

Multi centre, Randomised, Double blind, Controlled, Parallel (100 subjects per arm), Intra-subject & inter subject comparisons


Condition or disease Intervention/treatment Phase
Acne Combination Product: Epiduo Drug: Salicylic Acid Other: Hydréane légère Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 100 subjects per arm
Masking: Double (Participant, Investigator)
Masking Description: double blind
Primary Purpose: Treatment
Official Title: Multicentric, Parallel, Randomized, Double Blind Study Under Dermatological Control to Evaluate the Anti-acne Efficacy of a Dermo-cosmetic Product (Fla 688977 33) Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer (Hydréane légère, Cosmétique Active International) During a 12-week Application Period in Male and Female Subjects Presenting With Mild to Moderate Acne
Estimated Study Start Date : February 18, 2019
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Cosmetics

Arm Intervention/treatment
Experimental: Salicylic acid & Epiduo 0.1%-2.5% Topical Gel

Salicylic acid: Once-a-day, on the morning, during 12 weeks.

Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks.

Combination Product: Epiduo
100 per arm Adapalene/ Benzoyl Peroxide

Drug: Salicylic Acid
Salicylic Acid

Placebo Comparator: Hydréane légère & Epiduo 0.1%-2.5% Topical Gel

Hydréane légère: Once-a-day, on the morning, during 12 weeks.

Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks.

Combination Product: Epiduo
100 per arm Adapalene/ Benzoyl Peroxide

Other: Hydréane légère
moisturizer




Primary Outcome Measures :
  1. Evaluation of the anti-acne efficacy 1 (number of the retentional and inflammatory lesions) [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    Change in the number of the retentional (open & closed comedones) and inflammatory lesions (papulae, pustulae & nodules (if applicable)) on face after a 12-week application period At Week 0 (before any application) and Week 12 (after a 12-week application period), a counting of the retentional (open & closed comedones) and inflammatory lesions (papulae, pustulae & nodules (if applicable)) will be performed by a Dermatologist.

    The counting will be broken down on several parts of the face (forehead, left and right cheeks and chin).



Secondary Outcome Measures :
  1. Evaluation of the anti-acne efficacy 2 (number of the retentional and inflammatory lesions) [ Time Frame: Week 4 and Week 8 (intermediary times point) ]

    Change in the number of the retentional (open & closed comedones) and inflammatory lesions (papulae, pustulae & nodules (if applicable)) on face after 4 and 8-week application period At Week 4 (after a 4-week application) and Week 8 (after a 8-week application period), a counting of the retentional (open & closed comedones) and inflammatory lesions (papulae, pustulae & nodules (if applicable)) will be performed by a Dermatologist.

    The counting will be broken down on several parts of the face (forehead, left and right cheeks and chin).


  2. Change in the acne stage on face according to the Global Acne Evaluation scale after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]
    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), determination of the acne stage will be performed by the Dermatologist according to the Global Acne Evaluation scale (score min:0 to score max:5). More the score decreased, more the treatment is efficient.

  3. Change in the residual marks visibility after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]
    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the residual marks visibility of acne (hyperpigmentation) will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:numerous). More the score decreased, more the treatment is efficient.

  4. Change in the pores visibility after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]
    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the pores visibility will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:numerous). More the score decreased, more the treatment is efficient.

  5. Change in the skin shininess after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]
    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the skin shininess will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:high). More the score decreased, more the treatment is efficient.

  6. Change in skin greasiness after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]

    At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse.

    The CL measurements (quantity of sebum (casual level)) will be taken using a SEBUMETER®.

    The unit is in µg sebum/cm² of the skin. Only one measurement per subject will be taken in the middle of the forehead. More the value decreased, less the skin is greasy.


  7. Change in skin moisturizing after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]

    At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse.

    The measurements will be taken using a CM 825 PC CORNEOMETER®. The hydratation values are expressed in arbitrary units ranging from approximately 0 to 120.

    Three measurements per subject will be taken on the right cheekbone. More the value increased, more the skin is moisturize.


  8. Change in skin ph after 4, 8 and 12-week application period [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]

    At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse.

    The measurements will be taken using a SKIN PH METER 900®. The result will be expressed in pH units. Only one measurement per subject will be taken on the left cheek, near to the side of the nose. More the value decreased, more the ph is acid.


  9. Total number of hair follicles per cube at a mean depth of 38 µm after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  10. Diameter of the infundibulum in µm after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  11. Aspect of the border (thickness) (number and percentage) after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  12. Onion like appearence (number and percentage) after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  13. Presence of amorphous material into the infundibulum (number and percentage) after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  14. Signs of inflammation (number and percentage) after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  15. Vascularization (number and percentage) after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  16. Presence of Demodex mites (number and percentage) after a 12-week application period [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes.

    Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular).

    Confocal images will be analyzed by two confocal microscopy experts.


  17. Analysis of the efficacy on the skin quality using a questionnaire [ Time Frame: Week 12 (final time point) ]

    Subjects will complete an efficacy questionnaire at the last visit (after a 12-week application period of the Investigational Product (cosmetic product & drug)).

    The following items will be evaluated by the subjects:

    1. Imperfections are less visible
    2. The skin is cleansed/purified
    3. The complexion is homogeneous / uniform
    4. The skin is comfortable
    5. The skin is like hydrated
    6. The skin is smoother
    7. The skin is softer
    8. The skin is suppler
    9. The skin is less brilliant
    10. The skin is matified
    11. Excess sebum is reduced
    12. The skin has a matte touch
    13. The pores of the skin are tightened
    14. Redness of the skin are reduced
    15. The skin texture is refined
    16. The marks of the skin are less visible

    The following scale will be used:

    • Agree ("D'accord")
    • Somewhat agree ("Plutôt d'accord")
    • Neither agree, nor disagree ("Ni d'accord ni pas d'accord")
    • Somewhat disagree ("Plutôt pas d'accord")
    • Disagree ("Pas d'accord")

  18. Analysis of the local tolerance using clinical assessments [ Time Frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point) ]

    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), a clinical assessment of the face skin condition will be performed by the Dermatologist:

    • Physical signs: erythema, dryness and scaling
    • Functional signs*: tightness, prickling, itching, burning sensation and others

    The following scale will be used:

    Rating 0: none ("absence") Rating 1: slight ("léger") Rating 2: moderate ("modéré") Rating 3: severe ("sévère")

    * During the study, the subjects will have to record any skin discomfort, intensity (slight, moderate or severe) and duration in their daily log. Functional signs will be assessed by the Dermatologist from a review of the daily log and interrogatory of the subject.

    In addition, at W12 (after a 12-week application period), the Dermatologist and the subject.


  19. Products overall tolerance appreciation by the Dermatologist and the subject [ Time Frame: Week 12 (final time point) ]

    In addition, at Week 12 (after a 12-week application period), the Dermatologist and the subject will state about the overall tolerance of the IP (cosmetic product & drug) based on rating scale:

    • Excellent tolerance
    • Good tolerance
    • Medium tolerance
    • Poor tolerance

  20. Analysis of the cosmetic acceptability using a questionnaire [ Time Frame: Week 12 (final time point) ]

    Subjects will complete a cosmetic acceptability questionnaire concerning the cosmetic product at the last visit.

    The following items will be evaluated by the subjects:

    1. The product is easy to spread
    2. The product is easy to apply
    3. The product penetrates quickly
    4. The color of the product is pleasant
    5. The scent of the product is pleasant
    6. The aspect of the product is pleasant
    7. The texture of the product is pleasant
    8. The texture is comfortable
    9. The product doesn't leave the skin sticky
    10. The product doesn't leave a greasy film on the skin
    11. The product leaves a silky effect
    12. The product does not go noodles

    The following scale will be used:

    • Agree ("D'accord")
    • Somewhat agree ("Plutôt d'accord")
    • Neither agree, nor disagree ("Ni d'accord ni pas d'accord")
    • Somewhat disagree ("Plutôt pas d'accord")
    • Disagree ("Pas d'accord")

  21. Evaluation of the skin microbiota using sampling (if applicable) [ Time Frame: Week 0 (baseline) and Week 12 (final time point) ]

    At Week 0 and at Week 12, microbiota sampling will be performed by the same sampler (technician/nurse).

    Skin microbiota sample will be collected on one test site of 4 cm2 on the middle of the left cheek and using aseptic techniques under sterile airflow generated by a portable hood.

    According to the results of the primary variable, the Sponsor will decide to go ahead with the microbiota analysis which will be done by INRA Transfert.

    DNA will be extracted from the swabs. PCR amplification will be performed for each DNA sample. DNA will be PCR amplified. Cleaned pools will be sequenced on the Illumina MiSeq platform.

    Sequences will be then de-replicated and a database containing one sequence for each operational taxonomic unit will be generated.

    Interpretation of these results will be done by Mercurialis.


  22. Analysis of the number of subject with adverse event related to the study product [ Time Frame: From Week 0 (baseline) to Week 12 (final time point) ]
    Adverse Events will be collected during all the study from Week 0 to Week 12



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and/or female subjects aged 16 to 35 years
  2. Subjects presenting with mild to moderate acne (stage 2 or stage 3 with at least 12 inflammatory lesions on face according to the Global Acne Evaluation)
  3. Female subjects of child-bearing potential who:

    • use the same reliable hormonal contraceptive method (oral contraceptive, implant, intra-uterine device, patch, cervical cap, vaginal ring and injection) for at least 3 months prior to study inclusion and throughout the study or
    • use a reliable non-hormonal contraceptive method (copper intra-uterine device, condoms, diaphragm, cervical cap and spermicide) for at least 1 month prior to study inclusion and throughout the study or
    • have no sexual intercourse and agreeing not to have any throughout the study or
    • are surgically sterile (oophorectomy, hysterectomy or tubal ligation),
  4. Subjects and/or all legal representatives (for minor subjects) who have given written informed consent
  5. Subjects who are willing to comply with the study requirements
  6. Subjects with Social Security (health insurance) coverage (according to the French requirements)

Exclusion Criteria:

  1. Subjects with any systemic disorder or face dermatoses other than acne that would in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, or psoriasis)
  2. Subjects with a condition or receiving a medication and/or with a history of medical/surgical events which, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
  3. Subjects with a history of skin cancer
  4. Female subjects who are pregnant (positive urine pregnancy test) or lactating or who are planning to become pregnant during the study
  5. Subjects who have started, stopped or changed of hormonal treatment (contraception, thyroid …) in the 3 months prior the study inclusion
  6. Subjects with hypersensitivity to the active substances of Epiduo (Adapalene and/or benzoyl peroxide) or to one of its excipients
  7. Subjects who are sensitive to peroxides (oxygenated water)
  8. Subjects who have received isotretinoin treatment in the 6 months prior to study inclusion
  9. Subjects who have been exposed to excessive UV light (natural or artificial) in the 1 month prior to the study inclusion or having planned excessive UV light exposure during the study (e.g. ski holidays, holidays in the tropics…)
  10. Subjects who have used systemic drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion
  11. Subjects who have used topical drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 2 weeks prior to study inclusion
  12. Subjects who have used scrub, anti-seborrheic topical cosmetic products and/or who have applied self-tanning products on face in the 1 week prior the study inclusion
  13. Subjects who have applied cosmetic products for more than 5 consecutive days with alpha hydroxyl-acids, vitamin C, hyaluronic acids in the 1 week prior the study inclusion
  14. Subjects having washed the face and/or the hair the day of the study inclusion (only water is accepted the morning of the study inclusion)
  15. Subjects having applied any topical products on face (including make-up) the day of the study inclusion
  16. Subjects who have planned a major surgery during the study requiring hospitalization under general anesthesia and the use of systemic or topical drugs (e.g. antibiotics, anti-inflammatory) for more than 1 week
  17. Subjects who declare to be deprived of their freedom by administrative or legal decision or who are under guardianship
  18. Subjects who cannot be contacted by telephone in case of emergency
  19. Subjects belonging to the staff of the study centre
  20. Subjects in an exclusion period or participating in another biomedical research study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03832647


Contacts
Layout table for location contacts
Contact: karine duhamelle +33153684684 karine.duhamelle@intertek.com
Contact: caroline derome +33153684688 caroline.derome@intertek.com

Sponsors and Collaborators
Vichy Laboratoires
  Study Documents (Full-Text)

Documents provided by Vichy Laboratoires:

Publications of Results:

Layout table for additonal information
Responsible Party: Vichy Laboratoires
ClinicalTrials.gov Identifier: NCT03832647     History of Changes
Other Study ID Numbers: VCA 18-01
2018-A02481-54 ( Other Identifier: Agence National de Sécurité du médicament et des produits de santé )
First Posted: February 6, 2019    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Adapalene, Benzoyl Peroxide Drug Combination
Benzoyl Peroxide
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Salicylic Acid
Adapalene
Salicylates
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Infective Agents
Antifungal Agents
Keratolytic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action